IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site

Trial StartProSense® ChoICE StudyPositive

AI Analysis

Summary

IceCure Medical announced the addition of Legacy Health in Portland, OR as a clinical site for the ProSense® ChoICE Study, expanding enrollment for its minimally-invasive cryoablation technology in low-risk breast cancer treatment.

Clinical Trial Data

Importance:3/10

Sentiment:

0.30

clinical trial expansioncryoablationbreast cancerminimally invasivenew site enrollment

Related Companies

$ICCM

Read the original article

Published by PR Newswire Biotech on October 6, 2026 12:25 PM

Read Original